Demand for Liver Disease Drugs to Surge Through 2030

The global liver disease treatment market is projected to grow from US$46 billion in 2024 to US$69.1 billion by 2030, with a 7.1% CAGR, according to BCC Research. The forecast covers major markets including the United States, Canada, Mexico, the United Kingdom, Germany, China, India, and Brazil.

“Increasing liver disease cases and advances in biotech are reshaping treatment approaches, with personalized therapies and fibrosis-targeted drugs playing a significant role,” noted BCC Research in its announcement.

The projected growth reflects rising incidences of conditions such as hepatitis, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and liver cancer. These are being driven by factors including aging populations, poor dietary habits, alcohol use, and rising obesity and diabetes rates globally. The analysis covers disease types, regional market dynamics, clinical trials, regulatory updates, and newly approved therapies.

North America is expected to remain the largest regional market, with an increase from US$20.8 billion in 2024 to US$31.6 billion by 2030, representing a regional CAGR of 7.3%. Hepatitis remains the dominant segment across all regions.

Recent developments in liver therapeutics are also supporting the market’s expansion. The US Food and Drug Administration (FDA) approved Rezdiffra in 2024 as the first treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. Another new therapy, Livdelzi, received accelerated approval for treating primary biliary cholangitis (PBC) in adults not responding to or intolerant to first-line treatment with ursodeoxycholic acid.

Government-led public health campaigns and vaccine programs have further contributed to early diagnosis and increased treatment uptake. BCC Research cited both private and public sector efforts in expanding access and awareness as key market drivers, alongside continued clinical research and pharmaceutical investment.

Startups such as Akero Therapeutics, Galectin Therapeutics, and Tessera Therapeutics are also entering the space, developing next-generation liver disease therapies. Meanwhile, major market players include AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Findings underscore a shift toward precision medicine in hepatology, with gene therapy and individualized treatments gaining traction. Industry stakeholders are closely monitoring evolving regulatory frameworks, patient demand, and treatment protocols to adapt to these trends.